A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006621/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine the efficacy of ponatinib in patients with chronic
myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or
with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who either are
resistant or intolerant to either dasatinib or nilotinib, or have the
(T)hreonine-315-(I)soleucine (T315I) mutation.
提供机构：
Vivli
创建时间：
2021-01-27
